Harmony Biosciences Holdings, Inc. (HRMY) Dividend History

Company News

• Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight

  The Developmental and Epileptic Encephalopathies (DEE) market is expected to grow significantly due to approved medications like EPIDIOLEX, rising demand for novel treatments, and the introduction of potential emerging therapies. However, the discontinuation of emerging therapies may impede this growth.

  GlobeNewswire Inc.
• Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

  Harmony Biosciences Holdings, Inc. (HRMY) reported better-than-expected earnings and revenue for the second quarter of 2024. However, the company's stock has underperformed the market so far this year, and the earnings outlook is unfavorable, leading to a Zacks Rank #5 (Strong Sell) rating.

  Zacks Investment Research

  Featured Companies: FATE
• Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In

  Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharmaceutical applications and a diversification of medical cannabis products. Bingham notes that the rescheduling will be a game-changer for research, allowing scientists to pursue careers studying cannabinoids without risking their careers. "For the last 50 years, studying cannabinoids was a career ender for young scientists. Now, they will be able to pursue it and come up with fascinating discoveries."  Economic And Operational Impacts The rescheduling is likely to alleviate financial pressures on cannabis businesses, notably by eliminating certain tax burdens, which Bingham says will "inject much more cash and capital into the industry." This financial liberation is expected to accelerate research and development, particularly in medical cannabis, potentially attracting substantial investment from healthcare and pharmaceutical companies. He also anticipates ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: ABBV CRBP CRDL JAZZ PFE
• Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript

  HRMY earnings call for the period ending March 31, 2024.

  The Motley Fool
• The Zen Ten - My Top Picks For 2024

  I’ve been publishing the Zen Ten list each December since 2008. In this article, I reveal my new stock picks for 2024 and present a quick review of last year's picks. Read more here...

  Seeking Alpha

  Featured Companies: ACGL AMZN CTVA FICO FTNT IMKTA KNSL LPLA MELI META MHO MSCI MSFT NVDA RS TDG UNH